CHICAGO (Reuters) – A pregnancy hormone that relaxes blood vessels appeared to reduce symptoms of acute heart failure and improve survival, according to a preliminary study released by U.S. researchers on Sunday.

They said the hormone relaxin, which is being developed by privately held Corthera Inc of California, was safe, and showed signs of reducing the risk of death from heart problems during the study.

The findings suggest that "early administration of this drug, in addition to standard therapy, might be associated with more rapid, sustained and complete resolution of acute heart failure, as well as with more favorable long-term outcomes," John Teerlink of the University of California, San Francisco, and colleagues wrote in the journal Lancet.

"if established in larger studies, the benefits of relaxin might represent an important advance in the treatment of patients with acute heart failure," the researchers wrote.

In pregnancy, the hormone helps relax and lengthen the cervix to prepare for childbirth, but it is also thought to be a natural vasodilator, widening blood vessels and allowing blood to flow more freely.

Vasodilators are often given to people with high blood pressure, which is common in heart failure, a condition in which the heart gradually loses its ability to pump blood efficiently, leaving organs starved for oxygen.

Teerlink and colleagues studied 234 elderly patients with heart failure and high blood pressure who were given either a 48-hour intravenous infusion of the drug or a placebo.

They found it was safe and helped to reduce shortness of breath in 40 percent of patients who received a moderate dose of the drug, compared with 23 percent who took a placebo.

It also reduced the number of patients in the study who died from heart problems or were readmitted to the hospital within two months for kidney failure compared with the placebo, according to the results, which were also presented at the American College of Cardiology meeting in Florida.

An estimated 5.3 million Americans have heart failure, a chronic but often deadly condition that will cost $34.8 billion this year for direct and indirect U.S. treatment costs, according to the American Heart Association.

© Copyright (c) Reuters

Blighted ovum: what causes it? from Mary Gallenberg, M.D.

A blighted ovum, also called an anembryonic pregnancy, occurs when a fertilized egg develops a placenta and membrane but no embryo — often due to chromosomal abnormalities in the fertilized egg. A blighted ovum usually occurs in the first few weeks of pregnancy, often before a woman even knows she’s pregnant.

With a blighted ovum, a woman may miss a period and have a positive pregnancy test. this is because the placenta secretes human chorionic gonadotropin (HCG), a pregnancy hormone. Symptoms of early pregnancy — such as fatigue and breast tenderness — are possible as well. but when the placenta stops growing and hormone levels decrease, the pregnancy symptoms subside. At this point, minor abdominal cramping and light spotting or bleeding are possible. an ultrasound will show an empty gestational sac.

A blighted ovum eventually results in miscarriage. Some women choose to wait for the miscarriage to happen naturally, while others take medication to trigger the miscarriage. in some cases, a procedure called dilation and curettage (D&C) is used to remove the placental tissues.

Most women who’ve had a blighted ovum go on to have successful pregnancies. If you experience multiple consecutive miscarriages, you might consider testing to identify any underlying causes.

Next questionPregnancy and hot tubs: What’s the risk?

© 1998-2010 Mayo Foundation for Medical Education and Research (MFMER). all rights reserved. A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.com," "EmbodyHealth," "Enhance your life," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.